JCR Pharmaceuticals Full Year 2024 Earnings: Misses Expectations

JCR Pharmaceuticals (TSE:4552) Full Year 2024 Results

Key Financial Results

• Revenue: JP¥42.9b (up 25% from FY 2023).
• Net income: JP¥5.51b (up 46% from FY 2023).
• Profit margin: 13% (up from 11% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: JP¥44.13 (up from JP¥30.34 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

JCR Pharmaceuticals Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 24%.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 4.5% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for JCR Pharmaceuticals that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.